Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted 03 May, 2013 and appeared in  ObesityType 2 DiabetesGastroenterologySurgeryIssue 675

No Link between Diabetes Remission, Weight Regain after Gastric Bypass

Weight regain among diabetic patients who have undergone gastric bypass is not associated with remission of diabetes....

Advertisement

Researchers evaluated 652 patients who underwent laparoscopic Roux-en-Y gastric bypass (LRYGBP) at a single facility between March 2003 and December 2009. Follow-up was performed for a mean of 2.88 years after surgery. The cohort included 170 patients who had preoperative type 2 diabetes mellitus (T2DM).

Across all participants, the mean maximum excess weight loss (EWL) was 77.1%, with two-thirds of participants regaining an average of 19.1% of maximum EWL during follow-up. Most patients with T2DM (82.7%) were in remission upon completion of follow-up, with 5.8% of those with diabetes experiencing recurrence after remission. Recurrence was significantly associated with insulin use (75% compared with 18%) and longer T2DM duration (12.3 years vs. 6 years) compared with those who did not experience recurrence. Investigators said neither the maximum EWL nor the amount of weight regained were significantly different between recurrent and nonrecurrent patients.

"Weight regain after LRYGBP is common, but not associated with remission," the researchers concluded. "Recurrence of T2DM after remission … is associated with longer duration of T2DM and insulin use. Early surgical intervention for morbidly obese patients with T2DM should be recommended to maximize remission rates."

Presented at the Society of American Gastrointestinal and Endoscopic Surgeons Annual Meeting in Baltimore. April 17, 2013, Taitano AA. P005: Weight Regain Does Not Impact Remission of Diabetes After Gastric Bypass.  

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 03 May, 2013 and appeared in  ObesityType 2 DiabetesGastroenterologySurgeryIssue 675

Past five issues: Issue 744 | Diabetes Clinical Mastery Series Issue 203 | Issue 743 | Diabetes Clinical Mastery Series Issue 202 | SGLT-2 Inhibitors Special Edition August 2014 |

2014 Most Popular Articles:

Low-carb Diet Recommended for Type 1 and 2 Diabetes Patients
Posted August 01, 2014
New Combination of Diabetes Drugs Have Synergistic Effect
Posted August 08, 2014
FDA Approves J&J's Invokamet Combo (SGLT-2 + Metformin)
Posted August 15, 2014
New Encapsulated Beta-Cell Replacement Therapy for Type 1 Diabetes
Posted August 08, 2014
Diabetic Neuropathy Improved with Vegan Diet
Posted August 22, 2014
During Prolonged Low-Intensity Exercise, Caffeine Alters Blood Glucose
Posted August 15, 2014
CDC: 40% of American Adults Will Develop Diabetes
Posted August 22, 2014
SGLT2 Inhibitor Empagliflozin Wins FDA OK
Posted August 08, 2014
Early Insulin Delays Diabetes But Are There Negative Consequences?
Posted August 15, 2014
Peripheral Neuropathy Associated with CV Disease and Stroke in Type 2 Diabetes Patients
Posted August 15, 2014


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Bernstein | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
When Afrezza is available, will you prescribe it immediately or wait until it has been on the market for a while?
CME/CE of the Week
Ronald Tamler, MD, PhD, MBA

Category: General Diabetes
Credits: .75
Search Articles On Diabetes In Control